[{"id":"13d156b8-c503-459e-ab56-2c6df651256c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05333809","created_at":"2022-04-19T23:53:52.843Z","updated_at":"2024-07-02T16:36:11.817Z","phase":"Phase 2","brief_title":"Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05333809","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-04-20"},{"id":"efef7fc3-6ed0-4537-9751-b41c852c3812","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454620","created_at":"2021-01-18T17:02:02.918Z","updated_at":"2024-07-02T16:36:16.137Z","phase":"Phase 1b/2a","brief_title":"A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy","source_id_and_acronym":"NCT03454620","lead_sponsor":"Green Cross Corporation","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" EGFR expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • GC-1118A"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 09/17/2021","primary_completion_date":" 09/17/2021","study_txt":" Completion: 01/10/2022","study_completion_date":" 01/10/2022","last_update_posted":"2022-03-03"},{"id":"12703e6d-ae4a-48dc-8f0f-c5ca0a1dc374","acronym":"","url":"https://clinicaltrials.gov/study/NCT04466254","created_at":"2021-01-18T21:27:57.019Z","updated_at":"2024-07-02T16:36:26.025Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04466254","lead_sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • BRAF wild-type + NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • oxaliplatin • CPGJ-602"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 03/30/2022","study_completion_date":" 03/30/2022","last_update_posted":"2021-08-23"}]